Beyond the Jab: Protecting Muscle, Metabolism and Momentum on GLP-1s

By Rick Miller, Clinical Director, Miller Health and HCPC-registered dietitian. Miller Health is a diagnostic-led men’s health practice at 25 Harley Street, London.

A GLP-1 medication will reliably reduce a man’s body weight. That is not the clinical question worth asking. The question is what kind of weight he loses, what happens to his metabolism while he loses it, and what holds once the medication stops. For the men I assess, who are typically in their forties and fifties and carrying the metabolic cost of a demanding professional life, those three questions decide whether a GLP-1 becomes a genuine clinical advance or an expensive way to lose the wrong tissue.

Semaglutide and tirzepatide have changed what is achievable in weight management, and patients at clinics like The Nine Clinic are right to be interested. Used well, alongside the right clinical support, they are among the most effective metabolic tools available. Used in isolation, prescribed and left to run, they expose a man to a set of risks that rarely get discussed at the point of prescription. This article sets out what those risks are and how a dietitian-led pathway addresses each one.

What the medication actually does

GLP-1 receptor agonists mimic glucagon-like peptide-1, a hormone released by the gut after eating. They slow gastric emptying, signal satiety to the brain, and improve insulin sensitivity. The practical result is a substantial and sustained reduction in appetite. Most men eat considerably less without the constant effort that usually accompanies caloric restriction, and the weight comes off.

The mechanism is well-characterised and the trial evidence is strong. Research published in the New England Journal of Medicine has demonstrated clinically significant weight reduction across large patient populations on both semaglutide and tirzepatide. This is established science, not early signal. The point of clinical interest is not whether these drugs work. It is what the body does in response to rapid weight loss, and that is where the medication stops being the whole answer.

The lifestyle multiplier

A GLP-1 reduces how much a man eats. It does not tell his body what to do with the deficit. That instruction comes from everything around the medication: protein intake, resistance training, sleep, and the timing of food across the day.

When a man loses weight rapidly without those inputs, the body draws on lean tissue as well as fat. Skeletal muscle is metabolically expensive to maintain, and in a sharp deficit the body has no reason to protect it unless it is given one. The medication creates the deficit. Nutrition and training decide whether that deficit is paid in fat or in muscle. This is the difference between a man who finishes a course of treatment leaner, stronger and metabolically improved, and a man who finishes it lighter but diminished.

For the executive patient, this distinction is not cosmetic. Lean mass underpins energy, insulin sensitivity, resting metabolic rate and physical resilience. Losing it quietly undermines the exact qualities these men are trying to protect.

The four pitfalls

Muscle loss and sarcopenia risk. This is the central clinical concern. Studies of GLP-1 weight loss have found that a meaningful proportion of the total weight lost can come from lean mass when no protective protocol is in place. Meta-analyses in the weight-loss literature put lean tissue at a substantial share of total loss under rapid caloric restriction. For a man already in his fifties, who is losing muscle to age at a baseline rate, accelerating that loss is a serious matter. The period of active treatment is what I call the Lean Mass Window: the phase during caloric deficit or GLP-1 therapy when muscle tissue is most exposed and most in need of deliberate protection.

Gastrointestinal tolerance. Nausea, early fullness, constipation and reflux are common, particularly during dose escalation. Beyond the discomfort, these effects often push men toward eating less protein and fewer whole foods, precisely when protein intake matters most. Tolerance is manageable, but it has to be managed actively rather than endured.

The metabolic plateau. Weight loss slows and stops, often sooner than the patient expects. Part of this is adaptive: a smaller body burns fewer calories, and if lean mass has been lost, resting metabolic rate falls further. A plateau is frequently the body reporting that the approach needs adjusting, not a failure of willpower.

Regain on the off-ramp. This is the pitfall least discussed at prescription and most consequential. Appetite returns when the medication stops. If a man has lost muscle, his metabolic rate is now lower than before he started, and weight returns readily, frequently as fat. Without a planned, supervised off-ramp, a man can end a course of GLP-1 treatment metabolically worse off than he began. The medication was never the problem. The absence of a plan for stopping it was.

How a dietitian-led pathway addresses each one

Every one of these risks is addressable, and none of them is addressed by the prescription alone. This is the clinical case for a dietitian working alongside the prescribing doctor rather than after the fact.

The first lever is protein. Through a deficit, protein requirements rise rather than fall, and the evidence on preserving lean mass during weight loss is clear: higher protein intake, distributed across the day, substantially reduces muscle loss. Work from Stuart Phillips’ group at McMaster University has been central to establishing this. Setting and hitting an individualised protein target is the single most important nutritional intervention during GLP-1 treatment, and it rarely happens by accident, especially when appetite is suppressed and GI tolerance is variable.

The second lever is resistance training. Muscle responds to mechanical load. A structured resistance programme gives the body the signal to retain lean tissue through the deficit, and it does not require the patient to live in a gym. It requires the right stimulus, applied consistently.

The third lever is monitoring. Body composition, not bodyweight, is the measurement that matters. A DEXA scan distinguishes fat loss from muscle loss with precision a set of scales cannot. Tracking lean mass through treatment turns the Lean Mass Window from a blind risk into a managed variable, and lets the protocol be adjusted before muscle is lost rather than after.

The fourth lever is the off-ramp itself. A supervised reduction in medication, paired with a nutrition and training plan built to hold the result, is what separates durable change from temporary weight loss. The off-ramp should be planned at the start of treatment, not improvised at the end.

There is a further dimension that most weight-management frameworks omit. The timing of food relative to the body’s circadian phase influences metabolic efficiency independently of how much is eaten. Work from researchers including Satchin Panda at the Salk Institute has shown that when food is consumed, not only how much, shapes the metabolic response. For men whose professional lives push eating late into the evening, this is a practical and measurable consideration through a GLP-1 course, not a theoretical one.

When to bring a dietitian into the room

A GLP-1 is best understood as one component of a metabolic strategy, not the strategy itself. The doctors at The Nine Clinic provide the clinical oversight, the prescribing judgement and the continuity of care that this kind of treatment requires. What sits alongside that is the nutritional and body-composition work that determines the quality of the result: protein, training, monitoring and a planned off-ramp.

This is the work my team and I do at Miller Health. We assess body composition directly through DEXA at 25 Harley Street, set individualised protein and training protocols, and follow lean mass through treatment, so that what a man loses is fat and what he keeps is muscle and metabolic capacity. For men who want the full course held to that standard, from the first dose through to a supervised off-ramp, our Executive programme provides a sustained clinical relationship rather than a single appointment.

The right starting point is rarely the prescription. It is an honest picture of where a man actually stands: his body composition, his blood markers, his metabolic rate, read together rather than in isolation. With that in hand, a GLP-1 becomes a precise instrument rather than a blunt one.

A GLP-1 can be one of the most effective metabolic interventions available to a man in midlife, and for the right patient it is well worth considering. Whether it leaves him stronger or simply lighter depends entirely on what is done alongside it. That is a conversation worth having before the first injection, not after the last.

Rick Miller is an HCPC-registered dietitian and Clinical Director of Miller Health, the diagnostic-led men’s health practice at 25 Harley Street, London. He works alongside referring clinicians to provide dietitian-led metabolic and body-composition support for men on and around GLP-1 therapy. millerhealth.london